Open AccessThe use of metformin for polycystic ovary syndrome
Author(s) -
Т. А. Зыкова,
Г. А. Мельниченко,
А. В. Стрелкова,
B. A. Savenko,
E. V. Simonova,
И И Дедов
Publication year - 2004
Publication title -
problemy èndokrinologii
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.124
H-Index - 5
eISSN - 2308-1430
pISSN - 0375-9660
DOI - 10.14341/probl11302
Subject(s) - hyperinsulinemia , medicine , metformin , endocrinology , polycystic ovary , insulin resistance , insulin , stimulation , hyperinsulinism
Recently, there is strong evidence that insulin resistance and additive hyperinsulinemia are unique features of the polycystic ovary syndrome (PCOS). Additional studies evaluating the effect of agents affecting hyperinsulinemia are no doubt to be required before making official recommendations on their use in clinical practice. The paper presents data of 12-week metformin therapy in 65 females with PCOS, by analyzing the results of studies of insulinemia and glycemia during oral glucose tolerance tests (OGTT) performed prior to and following the therapy. Insulin resistance and sensitivity, p-cell functions, and a secretory response of insulin to glucose stimulation were evaluated by using mathematical models and by calculating surrogate OGTT indices validated with the reference clamp test. Metformin was found to exert a positive effect on metabolic disorders in females with PCOS via increased insulin sensitivity and a decreased integral secretory response on insulin to oral glucose stimulation, by creating conditions for an adequate response to the stimulus as better insulin-mediated glucose uptake with decreased compensatory hyperinsulinemia. Recovery of adequacy of a secretory response to glucose stimulation promotes a reduction in additive hyperinsulinemia only in PCOSfemales with p-cell dysfunction caused by a predominance of decreased peripheral insulin sensitivity, rather than secretory defect.